MoonLake Immunotherapeutics (MLTX) Free Cash Flow (2021 - 2026)
MoonLake Immunotherapeutics (MLTX) posted quarterly Free Cash Flow of -$66.3 million for Q1 2026, down 73.64% year-over-year from -$251.4 million in Q1 2025, and down 12.74% quarter-over-quarter from -$58.8 million in Q4 2025.
MoonLake Immunotherapeutics (MLTX) Free Cash Flow (2021 - 2026) Analysis & Trends
MoonLake Immunotherapeutics' Free Cash Flow history runs 6 years deep, the most recent figure standing at -$66.3 million for Q1 2026.
- In Q1 2026, Free Cash Flow fell 73.64% year-over-year to -$66.3 million; the TTM figure through Mar 2026 stood at -$224.2 million (down 59.73% YoY), while the FY2025 annual figure was -$196.0 million, down 67.4% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$66.3 million, down from -$58.8 million in the prior quarter.
- The five-year high for Free Cash Flow was -$9.0 million in Q1 2023, with the low at -$66.3 million in Q1 2026.
- The 5-year median for Free Cash Flow is -$20.8 million (2022), against an average of -$28.1 million.
- Peak annual rise in Free Cash Flow reached 67.08% in 2022, while the deepest fall reached 13074.98% in 2022.
- MoonLake Immunotherapeutics' Free Cash Flow stood at -$11.6 million in 2022, then slipped by 6.45% to -$12.3 million in 2023, then slumped by 294.11% to -$48.6 million in 2024, then dropped by 20.85% to -$58.8 million in 2025, then dropped by 12.74% to -$66.3 million in 2026.
- Business Quant data shows MLTX's Free Cash Flow at -$66.3 million in Q1 2026, -$58.8 million in Q4 2025, and -$44.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | MoonLake Immunotherapeutics | 1.40 Bn | 864.68 Mn | - | -55.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -55.56 Mn |
| Jun 30, 2026 | -55.56 Mn |
| Mar 31, 2026 | -66.29 Mn |
| Mar 31, 2026 | -66.29 Mn |
| Dec 31, 2025 | -58.79 Mn |
| Dec 31, 2025 | -58.79 Mn |
| Sep 30, 2025 | -44.54 Mn |
| Sep 30, 2025 | -44.54 Mn |
| Jun 30, 2025 | -54.53 Mn |
| Jun 30, 2025 | -54.53 Mn |
| Mar 31, 2025 | -38.18 Mn |
| Mar 31, 2025 | -38.18 Mn |
| Dec 31, 2024 | -48.65 Mn |
| Dec 31, 2024 | -48.65 Mn |
| Sep 30, 2024 | -25.62 Mn |
| Sep 30, 2024 | -25.62 Mn |
| Jun 30, 2024 | -27.89 Mn |
| Jun 30, 2024 | -27.89 Mn |
| Mar 31, 2024 | -14.95 Mn |
| Mar 31, 2024 | -14.95 Mn |